OABI (OmniAb, Inc.) Stock Financials & Earnings | Market Cap Arena

OABI (OmniAb, Inc.) Stock Financials & Earnings | Market Cap Arena

OABIOmniAb, Inc.

Mkt Cap$231M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$19M

Net Income (TTM)-$65M

EPS (TTM)-$0.57

Free Cash Flow (TTM)-$37M

Gross Margin73.5%

Op. Margin-369.6%

Net Margin-347.0%

FCF Margin-198.3%

P/S Ratio (TTM)12.4x

P/E Ratio (TTM)—

YoY Rev Growth-29.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$17M	$13M	-$8M
Q2 23	$7M	$2M	-$19M
Q3 23	$5M	$633K	-$20M
Q4 23	$5M	$5M	-$21M
Q1 24	$4M	$4M	-$23M
Q2 24	$8M	$8M	-$16M
Q3 24	$4M	$4M	-$20M
Q4 24	$11M	$11M	-$16M
Q1 25	$4M	$4M	-$19M
Q2 25	$4M	$4M	-$16M
Q3 25	$2M	-$2M	-$18M
Q4 25	$8M	$8M	-$16M

Valuation

Quarter	P/S	P/E
Q1 23	3.5x	—
Q2 23	3.5x	—
Q3 23	3.6x	—
Q4 23	6.8x	—
Q1 24	11.0x	—
Q2 24	10.6x	—
Q3 24	11.3x	—
Q4 24	8.8x	—
Q1 25	8.6x	—
Q2 25	10.0x	—
Q3 25	11.0x	—
Q4 25	12.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$28M	$27M
Q2 23	-$10M	-$11M
Q3 23	-$6M	-$7M
Q4 23	-$9M	-$9M
Q1 24	-$17M	-$18M
Q2 24	-$12M	-$13M
Q3 24	-$7M	-$7M
Q4 24	-$4M	-$4M
Q1 25	-$16M	-$16M
Q2 25	-$5M	-$5M
Q3 25	-$10M	-$10M
Q4 25	-$6M	-$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$234K
Q2 23	$813K
Q3 23	$490K
Q4 23	$107K
Q1 24	$926K
Q2 24	$751K
Q3 24	$152K
Q4 24	$46K
Q1 25	$209K
Q2 25	$165K
Q3 25	$182K
Q4 25	$9K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+75.8%	+38.5%
Q2 23	-3.5%	+33.9%
Q3 23	-20.7%	+17.0%
Q4 23	-86.4%	-1.4%
Q1 24	-77.5%	+4.1%
Q2 24	+9.6%	-8.9%
Q3 24	-23.8%	-7.1%
Q4 24	+124.1%	+2.5%
Q1 25	+9.3%	-12.7%
Q2 25	-48.8%	-15.9%
Q3 25	-46.3%	-14.8%
Q4 25	-22.5%	-9.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	35.8%
Q2 23	$7M	94.0%
Q3 23	$6M	115.2%
Q4 23	$6M	122.9%
Q1 24	$6M	149.8%
Q2 24	$5M	70.7%
Q3 24	$5M	127.2%
Q4 24	$5M	47.4%
Q1 25	$4M	99.8%
Q2 25	$4M	105.5%
Q3 25	$0	0.0%
Q4 25	$4M	43.1%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$14M	—	$7M
Q2 23	$14M	—	$7M
Q3 23	$14M	—	$7M
Q4 23	$15M	$8M	—
Q1 24	$15M	$8M	—
Q2 24	$14M	$8M	—
Q3 24	$13M	$7M	—
Q4 24	$13M	$7M	—
Q1 25	$13M	$8M	—
Q2 25	$11M	$8M	—
Q3 25	$10M	—	$5M
Q4 25	$14M	$7M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$23M	$91M	$114M
Q2 23	$21M	$82M	$103M
Q3 23	$21M	$75M	$97M
Q4 23	$16M	$71M	$87M
Q1 24	$19M	$50M	$69M
Q2 24	$21M	$36M	$57M
Q3 24	$27M	$32M	$59M
Q4 24	$28M	$32M	$59M
Q1 25	$11M	$33M	$44M
Q2 25	$18M	$23M	$42M
Q3 25	$29M	$31M	$60M
Q4 25	$26M	$29M	$54M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	99M	+5.8%
Q2 23	99M	+0.3%
Q3 23	100M	+0.4%
Q4 23	100M	+0.3%
Q1 24	101M	+0.6%
Q2 24	101M	+0.7%
Q3 24	102M	+0.9%
Q4 24	105M	+2.3%
Q1 25	106M	+0.8%
Q2 25	106M	+0.5%
Q3 25	115M	+8.1%
Q4 25	128M	+11.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$5M	7
FY 22	$622K	95
FY 23	$322K	106
FY 24	$232K	114
FY 25	$210K	89